Good news for tinnitus patients: The tinnitus therapy device tinniwell is covered by health insurances in Switzerland and Germany. After approval by an expert physician, the tinniwell will be covered by Helsana and Swica depending on the patient's tariff. In Germany, the full purchase price is refunded by the private health insurance Continentale depending on the insured's tariff.

For Resaphene Suisse AG, this milestone means that the developed therapy procedure can now become the standard in the treatment of chronic subjective tonal decompensated tinnitus. For health insurance companies, a significant reduction in costs is possible here. Until now, money has continuously been spent over the years on therapeutically meaningless procedures without evidence of efficacy.